O'Melveny-Led Samsung Biologics To Buy Drug Co. For $1.8B
Samsung Biologics said Monday it has agreed to acquire Swiss drug manufacturer PolyPeptide Group in an all-cash deal worth 1.46 billion Swiss francs ($1.8 billion), accelerating the South Korean company's expansion...To view the full article, register now.
Already a subscriber? Click here to view full article